Document is current
Any future updates will be listed below
-
Authors
Chehaibou, Ismael
Philippakis, Elise
Mané, Valérie
Lavia, Carlo
Couturier, Aude
Gaudric, Alain
Tadayoni, Ramin
- License Information
-
More Information
Article History
Received: 8 November 2020
Accepted: 22 March 2021
First Online: 13 April 2021
Declarations
:
: This research study was conducted retrospectively from data obtained for clinical purposes. An IRB official waiver of ethical approval was granted from the ethics committee of the French Society of Ophthalmology (IRB 00008855 Société Française d’Ophtalmologie IRB#1).
: Not applicable.
: Ramin Tadayoni: personal fees from Novartis (Basel, Switzerland), Bayer Healthcare (Leverkusen, Germany), Roche (Basel, Switzerland), Genentech (San Francisco, CA, USA), Allergan (Dublin, Ireland), Zeiss (Oberkochen, Germany), Alcon (Fort Wort, TX, USA). Aude Couturier: personal fees from Novartis (Basel, Switzerland), Bayer Healthcare (Leverkusen, Germany), Allergan (Dublin, Ireland). Alain Gaudric: personal fees from Novartis (Basel, Switzerland), Bayer Healthcare (Leverkusen, Germany), and from Thrombogenics (Leuvin, Belgium). The following authors have no financial disclosures: Ismael Chehaibou; Valérie Mané; Elise Philippakis; Carlo Lavia.
